|
1
|
Gorlick R and Bertino JR: Drug resistance
in colon cancer. Semin Oncol. 26:606–611. 1999.
|
|
2
|
Boose G and Stopper H: Genotoxicity of
several clinically used topoisomerase II inhibitors. Toxicol Lett.
116:7–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
4
|
Newman DJ, Cragg GM and Snader KM: The
influence of natural products upon drug discovery. Nat Prod Rep.
17:215–234. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ju HK, Baek SH, An RB, Bae K, Son KH, Kim
HP, Kang SS, Lee SH, Son JK and Chang HW: Inhibitory effects of
nardostachin on nitric oxide, prostaglandin E2, and tumor necrosis
factor-α production in lipopolysaccharide-activated macrophages.
Biol Pharm Bull. 26:1375–1378. 2003.PubMed/NCBI
|
|
7
|
Chiu LC, Ho TS, Wong EY and Ooi VE: Ethyl
acetate extract of Patrinia scabiosaefolia downregulates
anti-apoptotic Bcl-2/Bcl-X(L) expression, and induces apoptosis in
human breast carcinoma MCF-7 cells independent of caspase-9
activation. J Ethnopharmacol. 105:263–268. 2006.PubMed/NCBI
|
|
8
|
Peng J, Chen YQ, Lin JM, Zhuang ZQ, Xu W,
Hong ZF and Sferra TJ: Patrinia scabiosaefolia extract
suppresses proliferation and promotes apoptosis by inhibiting the
STAT3 pathway in human multiple myeloma cells. Mol Med Rep.
4:313–318. 2011.
|
|
9
|
Folkman J: Tumor angiogenesis: therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Folkman J and Shing Y: Angiogenesis. J
Biol Chem. 267:10931–10934. 1992.
|
|
11
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar
|
|
13
|
Cook KM and Figg WD: Angiogenesis
inhibitors: current strategies and future prospects. CA Cancer J
Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar
|
|
15
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jain RK: Transport of molecules in the
tumor interstitium: a review. Cancer Res. 47:3039–3051.
1987.PubMed/NCBI
|
|
17
|
Folkman J: How is blood vessel growth
regulated in normal and neoplastic tissue? GHA Clowes memorial
Award lecture. Cancer Res. 46:467–473. 1986.PubMed/NCBI
|
|
18
|
Strömblad S and Cheresh DA: Integrins,
angiogenesis and vascular cell survival. Chem Biol. 3:881–885.
1996.PubMed/NCBI
|
|
19
|
Breier G and Risau W: The role of vascular
endothelial growth factor in blood vessel formation. Trends Cell
Biol. 6:454–456. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
therapeutic implications. Semin Oncol. 29:10–14. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jain RK: Tumor angiogenesis and
accessibility: role of vascular endothelial growth factor. Semin
Oncol. 29:3–9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaya M, Wada T, Akatsuka T, Kawaguchi S,
Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F and Ishii S:
Vascular endothelial growth factor expression in untreated
osteosarcoma is predictive of pulmonary metastasis and poor
prognosis. Clin Cancer Res. 6:572–577. 2000.PubMed/NCBI
|
|
26
|
Maeda K, Chung YS, Ogawa Y, Takatsuka S,
Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular
endothelial growth factor expression in gastric carcinoma. Cancer.
77:858–863. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ishigami SI, Arii S, Furutani M, Niwano M,
Harada T, Mizumoto M, Mori A, Onodera H and Imamura M: Predictive
value of vascular endothelial growth factor (VEGF) in metastasis
and prognosis of human colorectal cancer. Br J Cancer.
78:1379–1384. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gille H, Kowalski J, Li B, LeCouter J,
Moffat B, Zioncheck TF, Pelletier N and Ferrara N: Analysis of
biological effects and signaling properties of Flt-1 (VEGFR-1) and
KDR (VEGFR-2). A reassessment using novel receptor-specific
vascular endothelial growth factor mutants. J Biol Chem.
276:3222–3230. 2001. View Article : Google Scholar
|
